Aripiprazole Tablet
Product Images NDC 50090-7125

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-7125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazolefigure1 (Aripiprazolefigure1)

A pharmacokinetic chart displaying Aripiprazole fold change and 90% confidence intervals in AUC and Cmax when coadministered with various inhibitors and inducers, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers like famotidine, and other drugs such as valproate, lithium, and lorazepam. The x-axis shows change relative to reference without interacting drug.*

FDA Label Image

Aripiprazolefigure2 (Aripiprazolefigure2)

A pharmacokinetic effect chart titled "Effect of Other Drugs on Aripiprazole." It displays dehydro-aripiprazole fold change and 90% confidence intervals for various interacting drugs, comparing AUC and Cmax changes relative to a reference with no interacting drug. Interacting drugs include ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazolefigure3 (Aripiprazolefigure3)

A chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs and pharmacokinetic parameters. The x-axis represents change relative to reference without interacting drug on a scale from 0.5 to 3.0. Listed drugs include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (including O-desmethylvenlafaxine), and escitalopram with measures such as AUC, Cmax, INR, and DMRP displayed.*

FDA Label Image

Aripiprazolefigure4 (Aripiprazolefigure4)

A chart titled "Aripiprazole Fold Change and 90% CI" depicting pharmacokinetic changes (AUC and Cmax) across special populations. The graph includes comparisons such as CYP2D6 poor vs. extensive metabolizer, gender, age groups, hepatic impairment severity, and renal impairment, showing change relative to reference values with confidence intervals.*

FDA Label Image

Aripiprazolefigure5 (Aripiprazolefigure5)

A pharmacokinetic (PK) chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax for various factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment, and severe renal impairment. The x-axis represents change relative to reference, with plotted points and error bars for each comparison group.*

FDA Label Image

Aripiprazolefigure6 (Aripiprazolefigure6)

A line graph showing the proportion of subjects with relapse over time in days from randomization for Aripiprazole compared to placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes two lines, one for Aripiprazole and one for placebo, indicating relapse rates in each group over time with a table of subjects at risk below the x-axis.*

FDA Label Image

Aripiprazolefigure7 (Aripiprazolefigure7)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, the y-axis shows the proportion with relapse, and the chart also indicates the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazolefigure8 (Aripiprazolefigure8)

A Kaplan-Meier survival curve chart comparing the proportion with relapse over days from randomization for Aripiprazole and Placebo groups. The solid line represents Aripiprazole, and the dashed line represents Placebo, with a table below showing the number of subjects at risk at various time points up to 364 days.*

FDA Label Image

Aripiprazolefigure9 (Aripiprazolefigure9)

A line graph depicting the change in YGTSS Total TIC Score from baseline over 8 weeks of treatment. It compares three groups: Abilify Low, Abilify High, and Placebo, showing the trend of score reductions during the treatment period.*

FDA Label Image

Aripiprazolestructure (Aripiprazolestructure)

Chemical structure of Aripiprazole, showing a complex arrangement of benzene rings, nitrogen atoms in piperazine and quinolinone moieties, chlorine substituents, and an ether linkage.*

FDA Label Image

Label Image (Lbl500907125)

Label for Aripiprazole 20 mg oral tablets by A-S Medication Solutions, package containing 30 tablets. The label includes storage instructions (68 to 77 degrees F), lot number, and a QR code for dosage packaging insert. The product is identified with NDC 50090-7125.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.